

# Accepted Manuscript

## Chronic Tearing Induced by Apremilast


Matthew R. Norris M.D. , Leonard Bielory M.D.

PII: S1081-1206(18)30525-8  
DOI: [10.1016/j.anai.2018.06.027](https://doi.org/10.1016/j.anai.2018.06.027)  
Reference: ANAI 2605

To appear in: *Annals of Allergy, Asthma Immunology*

Received date: 13 June 2018  
Revised date: 25 June 2018  
Accepted date: 26 June 2018

Please cite this article as: Matthew R. Norris M.D. , Leonard Bielory M.D. , Chronic Tearing Induced by Apremilast, *Annals of Allergy, Asthma Immunology* (2018), doi: [10.1016/j.anai.2018.06.027](https://doi.org/10.1016/j.anai.2018.06.027)



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Chronic Tearing Induced by Apremilast**

Matthew R. Norris, M.D.<sup>1</sup> and Leonard Bielory, M.D.<sup>2</sup>

<sup>1</sup> *Department of Medicine, Overlook Medical Center, Summit, NJ, USA*

<sup>2</sup> *Rutgers University Center for Environmental Prediction, New Brunswick, NJ, USA*

Correspondence: Dr. Leonard Bielory, Rutgers University Center for Environmental Prediction, New Brunswick, NJ, USA. Phone number: (973) 912-9817; Fax: (206) 333-1884. Emails: [drlbielory@gmail.com](mailto:drlbielory@gmail.com); [bielory@rutgers.edu](mailto:bielory@rutgers.edu)

Conflicts of Interest: none

Funding Source: none

Keywords: Apremilast; Epiphora; Phosphodiesterase 4 inhibitor; Dry eye

Abbreviations: Phosphodiesterase 4 (PDE-4); cAMP (cyclic adenosine monophosphate); FDA (Food & Drug Administration)

Word count: 947

Figures: none

Tables: none

The therapeutic potential of Phosphodiesterase 4 (PDE-4) inhibitors has been studied for various hyperproliferative skin disorders, such as psoriasis and atopic dermatitis. Inhibition of PDE-4 activity leads to elevated levels of intracellular cAMP; this results in anti-inflammatory effects in almost all inflammatory cells.<sup>1</sup> Apremilast is an oral PDE-4 inhibitor that is FDA approved for the treatment of psoriatic arthritis in adults as well as patients with moderate to severe plaque

Download English Version:

<https://daneshyari.com/en/article/10216665>

Download Persian Version:

<https://daneshyari.com/article/10216665>

[Daneshyari.com](https://daneshyari.com)